Short-term therapy for patients with hepatitis C virus genotype 2 or 3 infection

Olav Dalgard; Alessandra Mangia

doi:10.2165/00003495-200666140-00003

Short-term therapy for patients with hepatitis C virus genotype 2 or 3 infection

Olav Dalgard, Alessandra Mangia

IRCCS Casa Sollievo della Sofferenza

Research output: Contribution to journal › Article › peer-review

Abstract

In the past 10 years, progress has been made in the management of patients with chronic hepatitis C. A sustained virological response (SVR) is achieved in 80-85% of patients infected with hepatitis C virus (HCV) genotype 2 or 3 after 24 weeks of treatment with peginterferon-α and ribavirin. Treatment durations

Original language	English
Pages (from-to)	1807-1815
Number of pages	9
Journal	Drugs
Volume	66
Issue number	14
DOIs	https://doi.org/10.2165/00003495-200666140-00003
Publication status	Published - 2006

ASJC Scopus subject areas

Toxicology
Health, Toxicology and Mutagenesis

Access to Document

10.2165/00003495-200666140-00003

Cite this

@article{3ce8a4544cc6427e8e2a0a8ee050a1a0,

title = "Short-term therapy for patients with hepatitis C virus genotype 2 or 3 infection",

abstract = "In the past 10 years, progress has been made in the management of patients with chronic hepatitis C. A sustained virological response (SVR) is achieved in 80-85% of patients infected with hepatitis C virus (HCV) genotype 2 or 3 after 24 weeks of treatment with peginterferon-α and ribavirin. Treatment durations ",

author = "Olav Dalgard and Alessandra Mangia",

year = "2006",

doi = "10.2165/00003495-200666140-00003",

language = "English",

volume = "66",

pages = "1807--1815",

journal = "Drugs",

issn = "0012-6667",

publisher = "Adis International Ltd",

number = "14",

}

TY - JOUR

T1 - Short-term therapy for patients with hepatitis C virus genotype 2 or 3 infection

AU - Dalgard, Olav

AU - Mangia, Alessandra

PY - 2006

Y1 - 2006

N2 - In the past 10 years, progress has been made in the management of patients with chronic hepatitis C. A sustained virological response (SVR) is achieved in 80-85% of patients infected with hepatitis C virus (HCV) genotype 2 or 3 after 24 weeks of treatment with peginterferon-α and ribavirin. Treatment durations

AB - In the past 10 years, progress has been made in the management of patients with chronic hepatitis C. A sustained virological response (SVR) is achieved in 80-85% of patients infected with hepatitis C virus (HCV) genotype 2 or 3 after 24 weeks of treatment with peginterferon-α and ribavirin. Treatment durations

UR - http://www.scopus.com/inward/record.url?scp=33750044078&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750044078&partnerID=8YFLogxK

U2 - 10.2165/00003495-200666140-00003

DO - 10.2165/00003495-200666140-00003

M3 - Article

C2 - 17040112

AN - SCOPUS:33750044078

VL - 66

SP - 1807

EP - 1815

JO - Drugs

JF - Drugs

SN - 0012-6667

IS - 14

ER -

Short-term therapy for patients with hepatitis C virus genotype 2 or 3 infection

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this